Universal Vision Biotechnology Co (3218) Fair Value & Analysis
Healthcare · TW · Market cap 11.8B TWD
Fair value as of: Jul 21, 2026
From 24 valuation models · updated 20 days ago
Share price +2.8% over the past month.
A solid business, screening 87% undervalued on our models.
What matters now
- The rarer combination: high quality (73/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (203.05 TWD). The market is more pessimistic than our downside scenario.
- A fairly wide model range (203.05 TWD to 370.96 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 123.20 TWD – 359.77 TWD · fair‑value band 203.05 TWD – 370.96 TWD · the 145.00 TWD price screens below the 270.74 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Universal Vision Biotechnology Co (3218) currently trades at 145.00 TWD, while our model-based Fair Value estimate is 270.74 TWD, implying the stock looks roughly 86.7% undervalued today. The Quality Score stands at 73/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Universal Vision Biotechnology Co generated revenue of 4.2B TWD at a net margin of 23.0%. Revenue declined 3.0% year over year. It earns a return on equity of 26.7%. The balance sheet holds a net cash position of 284M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 203.05 TWD (bear case) to 370.96 TWD (bull case); at 145.00 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 19% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 87%, 3218 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (351.60 TWD) versus Asset-Based (31.81 TWD). Highest evidence: Growth DCF (80).
Notify me when 3218 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices.
Full company description
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as well as provides medical and scientific prescription eyeglasses. Further, it offers sunglasses, fashionable and reading glasses, and progressive lenses for presbyopia. Additionally, the company provides contact lenses for myopia, hyperopia, presbyopia, and astigmatism; Universal lutein supplements; Universal eyemall; and ortho-k and other products for myopia control. Further, it offers wholesale and retail of medical equipment, western medicine; purchase and sale of ophthalmic surgical investments, medical optical tool; corporate and medical project investment, therapeutic, and consulting services; ophthalmology clinics; healthcare investment management; and provides vision correction treatments, and operates a dispensing and retail business for eyeglasses. Additionally, the company provides various consulting services to partner clinics includes leasing, maintenance of ophthalmic equipment, procurement and sales of pharmaceuticals and consumables, business location assessment as well as store planning, IT integration and installment, brand marketing, and other professional administrative supports. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Universal Vision Biotechnology Co reported revenue of 4.2B TWD in FY2025 versus 2.6B TWD in FY2021, a compound +12.4%/yr. Reported net income was 1.0B TWD in FY2025, compounding +15.0%/yr from FY2021.
Watch 3218: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 42/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Universal Vision Biotechnology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Universal Vision Biotechnology Co (3218) overvalued or undervalued?
What is the fair value of 3218?
What is the quality score of 3218?
What is the revenue of Universal Vision Biotechnology Co (3218)?
What is the net profit margin of 3218?
Does Universal Vision Biotechnology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Universal Vision Biotechnology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.